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Abstract
Background: Pseudomonas aeruginosa is the major respiratory pathogen causing severe lung infections among CF
patients, leading to high morbidity and mortality. Once infection is established, early antibiotic treatment is able to
postpone the transition to chronic lung infection. In order to optimize the early detection, we compared the
sensitivity of microbiological culture and quantitative PCR (qPCR) for the detection of P. aeruginosa in respiratory
samples of not chronically infected CF patients.
Results: In this national study, we followed CF patients during periods between 1 to 15 months. For a total of 852
samples, 729 (86%) remained P. aeruginosa negative by both culture and qPCR, whereas 89 samples (10%) were
positive by both culture and qPCR.
Twenty-six samples were negative by culture but positive by qPCR, and 10 samples were positive by culture but
remained negative by qPCR. Five of the 26 patients with a culture negative, qPCR positive sample became later
P. aeruginosa positive both by culture and qPCR.
Conclusion: Based on the results of this study, it can be concluded that qPCR may have a predictive value for
impending P. aeruginosa infection for only a limited number of patients.
Background
Cystic fibrosis (CF) is one of the most common genetic
disorders, caused by mutations in the CFTR gene, cod-
ing for the Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) protein [1]. Mutations in this gene
lead to inactivity of the CFTR protein and/or reduced
expression of the protein at the cytoplasmic membrane
[2]. Improper functioning of the CFTR results in the
production of viscous mucus and in a defective innate
immunity [2,3]. The reduced functionality of the muco-
ciliary system and the ongoing inflammation result in an
increased sensitivity of the CF airways to infection by
bacterial pathogens, of which Pseudomonas aeruginosa
and Staphylococcus aureus are the most important.
Chronic lung infection with P. aeruginosa is a major
cause of morbidity and mortality among the CF patients
[4]. It is now well-established that early aggressive anti-
biotic treatment of new infection with P. aeruginosa is
successful in postponing chronic infection. Hence, it is
important to detect new infection with P. aeruginosa as
early as possible so that eradication treatment can be
started as soon as possible [5-7]. Currently, routine
detection and identification of P. aeruginosa in respira-
tory samples is done by conventional methods such as
culture and biochemical characteristics. Misidentification
can occur due to the variable phenotypic characteristics
of this species [8]. Moreover, the sensitivity of culture
might be limited, especially when compared to DNA
amplification based techniques. Thus far, however, only
one group has compared both approaches in a long
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In this national study, we followed CF patients during
periods between 1 to 15 months and we compared the
sensitivity of conventional culture techniques with qPCR
for the detection of P. aeruginosa in the respiratory




From January 2008 until May 2009, sputum, nasopharyn-
geal or throat swab samples were routinely collected
from 397 CF patients attending all but one of Belgian
CF-centres, i.e. Ghent University Hospital (UZG, Ghent),
Universitair Ziekenhuis Brussel (UZB, Brussels), St Luc
University Hospital (UCL, Brussels), Queen Fabiola
Children’s University Hospital and Erasme University
Hospital (ULB, Brussels), Antwerp University Hospital
(UZA, Antwerp), CF Center Liege (CHC - CHR, Liege).
Patients were seen every three months and sputum or
nasopharyngeal aspirate/throat swab samples were cul-
tured at every visit. Nasopharyngeal aspirates/throat swab
samples were collected in case the patients could not
expectorate. All 397 included patients, (median age:
14 years, range: 1-53 years), were considered as P. aerugi-
nosa free and not chronically infected according to the
criteria used by the different Belgian CF centers, i.e., the
European Consensus criteria [10] or those defined by Lee
et al. [11]. For the 252 patients with at least two respira-
tory samples (median: 3 samples, range: 2-11 samples),
the median follow-up time was 6 months (range: 1-
15 months). Patients with a P. aeruginosa positive culture
were treated according to the standard antibacterial
treatment protocols of each center, patients with only a
PCR positive result were not treated.
Sample processing
After arrival at the Laboratory Bacteriology Research
(LBR), sputum and nasopharyngeal samples were lique-
fied with Sputasol (Oxoid Ltd., Basingstoke, UK) (1:1,
vol/vol, 1 h incubation at 37°C). Throat swabs (ESwab,
Copan, Brescia, Italy) were vortexed in the liquid trans-
port medium present in the Eswab tube. For microbiolo-
gical culture, samples were immediately processed after
arrival. For qPCR, at least 200 μl of each sample was
stored at -80°C prior to DNA-extraction.
Culture and identification of the bacteria
Fifty μl of the samples were inoculated onto MacConkey
Agar plates (Becton Dickinson, Erembodegem, Belgium)
and 100 μl into 4 ml Cetrimide Broth (Fluka Biochem-
ika, Buchs, Switzerland) and incubated for at least 24 h
at 37°C at ambient atmosphere before examination.
Cetrimide Broth was subcultured by inoculating 50 μl
onto a Sheep Blood Agar plate (Becton Dickinson),
which was also incubated for at least 24 h at 37°C
before examination.
After a maximum of 5 days incubation, lactose nega-
tive colonies on MacConkey Agar were picked, subcul-
tured onto a 5% Sheep Blood Agar plate (Becton
Dickinson) and identified using tDNA-PCR [12].
DNA-extraction
Before DNA-extraction, respiratory samples were pre-
incubated with proteinase K, i.e. incubation of 200 μl
of each sample during 1 h at 55°C in 200 μl proteinase
K buffer (1 mg/ml proteinase K, 0.5% SDS, 20 mM
Tris-HCl, pH 8.3) with vortexing every 15 min. DNA
was extracted using the protocol Generic 2.0.1 on the
bioMérieux easyMAG Nuclisens extractor (bioMérieux,
Marcy-l ’Etoile, France). Final elution volume was
110 μl. This DNA-extraction protocol had been shown
previously to be the most sensitive of five different
methods [13].
Quantitative PCR
Quantitative PCR (qPCR), targeting the oprL gene
(NP_249664), was performed using primers PAO1 A
(5′ CAGGTCGGAGCTGTCGTACTC 3′) and PAO1 S
(5′ ACCCGAACGCAGGCTATG 3′) and hydrolysis
probe oprL TM (5′ FAM-AGAAGGTGGTGATCG-
CACGCAGA-BBQ 3′), manufactured by TIB Molbiol
(Berlin, Germany), as described previously [13]. The
reaction mixture contained 4 μl of the LightCycler Taq-
Man Master mix (Roche, Basel, Switzerland), 0.5 μM of
each primer, 0.1 μM of the hydrolysis probe, and 5 μl of
DNA extract. The final reaction volume was made up to
20 μl by adding water. Cycling was performed on the
LightCycler 1.5 (Roche) with an initial hold of 10 min at
95°C, 45 cycles at 95°C for 10 s, at 55°C for 30 s and at
72°C for 1 s.
Using qPCR, the concentration of P. aeruginosa in the
respiratory sample is determined as the cycle number
whereby the fluorescence signal intensity crosses the
detection threshold. This value is expressed as the quan-
tification cycle (Cq). The number of cycles is inversely
correlated to the concentration of P. aeruginosa in the
sample, e.g. a high cycle number indicates a low the
initial concentration of P. aeruginosa in the sputum.
Quality control of culture positive, PCR negative samples
To exclude PCR inhibition as an explanation for the
PCR negative, culture positive samples, the PCR mix,
containing the DNA extract of the sample, was spiked
with an internal amplification control (IAC), as
described by Khot et al. [14]. Briefly, 105 Jelly Fish oligo-
nucleotides (105 bp) (IAC-oligo), 0.4 μM forward primer
(IAC fw) and 0.4 μM reversed primer (IAC rev) primers
were added to the reaction mix, and a separate qPCR
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experiment, using the SybrGreen kit, was carried out
with primers hybridizing to the target DNA. When
compared to a set of control samples, i.e. culture and
qPCR P. aeruginosa positive samples to which the same
amount of IAC had been added, the PCR was consid-
ered as inhibited by (the DNA extract of) the sample,
when an increase of 3 Cqs could be observed.
To exclude that PCR negativity was due to primer
mismatch with the oprL gene of the P. aeruginosa isolates
for culture positive, PCR negative samples, oprL PCR was
carried out on DNA extracted from the P. aeruginosa
isolates, cultured from the same samples.
Ethics
The study was approved by the ethics committee from
Ghent University Hospital (project nr. 2007/503). Writ-
ten informed consent was obtained from the patients
> 18 years, or from the parents for the children.
Statistical analysis
Differences in Cq values were examined using
the Mann-Whitney U test and p values of < 0.05 were
considered as significant.
Results
A total of 852 samples was obtained from 397 not
chronically infected CF patients, from six out of the
seven Belgian cystic fibrosis centres. Of these, 729 sam-
ples (86%) from 307 patients remained P. aeruginosa
negative by culture and by P. aeruginosa specific qPCR
and 89 samples (10%) from 64 CF patients were both
P. aeruginosa culture and qPCR positive (Additional File
1, Table S1). For 11 of the 89 samples (12%), only one
culture method was positive, i.e. six times only MacCon-
key, five times only Cetrimide Broth. For these samples,
the mean qPCR Cq-value was 28.6, while for the samples
positive by both culture methods, the mean Cq value
was 26.4 (Table 1) (p > 0.05, not significant).
Twenty-six samples (3%), obtained from 26 CF patients,
were culture negative but qPCR positive (Additional File
1, Table S2). False positivity due to cross reaction with
other CF associated bacterial species could be excluded
because the specificity of the primer set had been tested
and confirmed on a broad set of common CF patho-
genic species [13].
For 23 of these 26 patients, at least one follow-up sam-
ple was obtained. Five of these became P. aeruginosa cul-
ture positive, of which four after a mean lag time of
3.5 months (range: 2-5 months)(Additional File 1, Table
S2, samples nr. 7, 19, 21, 23) and a fifth patient after a lag
time of nine months after the first qPCR positive sample
(Additional File 1, Table S2, sample nr. 8). The latter
patient had in between two culture negative, qPCR nega-
tive samples. Three other qPCR positive, culture negative
patients (Additional File 1, Table S2, samples nr. 3, 16,
22) had a previous sample that was P. aeruginosa culture
and qPCR positive (mean lag time 4.3 months, range 3-5
months). The follow-up samples of these three patients
were culture and qPCR negative. The average qPCR Cq
value (31.7) for these 26 samples was significantly higher,
compared with the Cq value of culture and qPCR positive
samples (26.4) (Table 1) (p < 0.001).
Ten samples, obtained from 9 patients, were P. aerugi-
nosa culture positive, but qPCR negative (Additional File
1, Table S3). For five of these ten samples (50%), only
one of the culture media yielded a positive result, i.e.
three samples remained negative on MacConkey Agar
and two sample in Cetrimide Broth. For all these culture
positive, PCR negative samples, PCR inhibition could be
excluded. Primer mismatch could also be excluded,
because the cultured P. aeruginosa isolates were oprL
qPCR positive. At least one follow-up sample could be
obtained for five of these patients, and for three the fol-
low-up sample(s) was/were culture and qPCR negative,
whereas for two patients the follow-up sample(s) was/
were culture and qPCR positive.
When taking culture as the gold standard, the PCR
had a sensitivity of 90%, a specificity of 85%, a positive
predictive value of 77% and a negative predictive value
of 99%.
For the samples with a dissimilar culture and qPCR
result, there was no relation with the presence of other
bacterial species isolated from the respiratory samples
(data not presented) and there was no linkage with the
sample type (data not presented).
Discussion
Early detection of Pseudomonas aeruginosa in respira-
tory samples of CF patients has become of utmost











78 + + 26.4 (17-32,
4.3)
6 + - 29.8 (25-32,
2.7)
5 - + 27.3 (22-32,
4.3)
26 - - 31.7 (20-34,
3.2)
2 + - NA
3 - + NA
5 + + NA
729 - - NA
NA: no amplification, SD: standard deviation
Deschaght et al. BMC Microbiology 2010, 10:245
http://www.biomedcentral.com/1471-2180/10/245
Page 3 of 6
importance, taking into account that it is now possible
to postpone chronic infection with the use of early
aggressive antibiotic treatment [5-7]. In most routine
microbiology laboratories, microbiological culture is still
the mainstay for detection of P. aeruginosa. However,
other detection methods that might be more sensitive
than microbiological culture still need evaluation and
validation [15].
Serological testing for P. aeruginosa antibodies has
been proposed as an alternative to culture for the early
establishment of new infection episodes. Several groups
reported that anti-P. aeruginosa antibodies can be
detected prior to P. aeruginosa detection by culture and
prior to the onset of chronic infection [16-18]. However,
in a cross-sectional study, da Silva Filho and colleagues
[19] found more patients positive with culture or PCR
than with serology.
In this prospective study, we evaluated whether qPCR
can improve early detection of P. aeruginosa in respira-
tory samples from CF patients, not yet chronically
infected with this organism.
During the last decade, several PCR formats and other
molecular methods for the detection of P. aeruginosa
have been developed [9,20-30]. Some groups found a
higher sensitivity of PCR in comparison with culture
and/or biochemical tests for the detection of P. aerugi-
nosa from respiratory samples of CF patients [9,19],
while others found no difference [28] or a lower sensi-
tivity for PCR [23]. In this study, we targeted the oprL
gene [13,21], previously shown to be a more sensitive
gene locus than the exotoxin A locus, when applied to
CF patient airway samples [9]. In a previous study [13],
we compared five DNA-extraction methods, six (q)PCR
formats and three culture techniques to optimize and
validate the detection of P. aeruginosa in sputum from
CF patients. In our hands, using a dilution series of
P. aeruginosa in sputum, the three culture methods
were equally sensitive to each other but also to the com-
bination of the most sensitive DNA extraction method
and the most sensitive amplification assay, i.e. probe
based qPCR.
Surprisingly, there is at present only one published
study in which P. aeruginosa detection by culture and
by qPCR is compared in a long term study [9]. These
authors concluded that PCR detected P. aeruginosa on
average 4.5 months prior to culture. In our opinion, this
conclusion should be interpreted with caution, because
also in their study only 5 of the 10 culture negative,
PCR positive patients became P. aeruginosa culture
positive during the follow-up period. It can also be
argued whether the cultured strain was identical as the
one causing PCR positivity 4-17 months prior to culture
positivity, given the long follow-up period and the fact
that the average conversion rate to culture positivity
among CF patients can be considered as relatively high.
Finally, the authors also found 5 culture positive, PCR
negative samples, for which PCR might have become
positive later on, however no follow-up data were
reported. In our study, we found that out of the 26
qPCR positive, culture negative samples, only 5 follow-
up samples became also P. aeruginosa culture positive,
of which one became double positive only in the third
follow-up episode after initial PCR positivity. The signif-
icantly higher Cq values of these 26 samples, compared
to the Cq values of double positive samples, suggest a
low P. aeruginosa inoculum in the respiratory sample
and may explain why the presence of P. aeruginosa was
missed by culture. Thus, PCR positivity may have had a
predictive value for impending infection in only 5 of the
26 patients, whereas in 21 patients a positive PCR signal
became negative again and did not predict a positive
culture at the next follow-up sample. For three of the
26 qPCR positive, culture negative patients, the previous
sample was P. aeruginosa culture and qPCR positive but
the follow-up samples were culture and qPCR negative.
This may indicate that qPCR still detected DNA of
already killed bacteria. Another 10 samples (1%) were
P. aeruginosa qPCR negative but culture positive. False
negativity of the qPCR was not the reason for the nega-
tive qPCR result, because qPCR inhibition and primer
mismatch could be excluded. Interestingly, for 5 of
these 10 patients, there was discordance between both
culture techniques, suggestive for borderline detection
by culture and thus a low inoculum of the pathogen.
Such discordance between culture results was observed
in only 11 out of 89 qPCR positive samples.
For many samples with discordant qPCR and culture
results, a low bacterial inoculum may be the explana-
tion. Based on our results in this study and a previous
study [13], both approaches have comparable sensitivity,
and at low inocula both may be at the border of their
detection limit. In addition, at low inocula the distribu-
tion of the bacteria in the sample may be more uneven
and because we used different parts of each sample to
perform qPCR respectively culture, randomization may
have influenced the qPCR and/or culture result nega-
tively. The presence of a low inoculum can be con-
cluded from the significantly higher Cq values of qPCR
positive/culture negative samples, compared to the
qPCR positive/culture positive samples and from the
fact that cultures were positive for only one of both
media used in 5 out of 10 qCPR negative/culture posi-
tive samples. Possibly other factors, such as sample type,
the presence of other bacterial species or the genotype
of the P. aeruginosa isolate might differentially influence
the ease with which P. aeruginosa can be detected by
culture versus qPCR. Further research is warranted on a
larger set of samples with discordant qPCR - bacterial
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culture results to determine the influence of some of
these factors.
Conclusions
The present study indicates that the currently used rou-
tine culture techniques perform equally well as DNA
amplification techniques for detection of P. aeruginosa
in respiratory samples of CF patients, not chronically
infected with P. aeruginosa. Looking at it from a differ-
ent angle, qPCR was both sensitive and specific com-
pared with a gold standard of culture.
These data, gathered on clinical samples, confirm the
results of our previous laboratory study in which culture
methods were equally sensitive to the combination of the
most sensitive DNA extraction method and the most
sensitive amplification assay, i.e. probe based qPCR [13].
Therefore, we may conclude that for this study, based
on a large amount of patients and samples, qPCR for
P. aeruginosa may have a predictive value for impending
P. aeruginosa infection in only a limited number of cases.
Additional material
Additional file 1: Table S1: Overview of the culture positive and
qPCR positive samples. Table S2: Overview of the culture negative
and qPCR positive samples. Table S3: Overview of the culture
positive and qPCR negative samples. Overview of all samples with at
least a P. aeruginosa positive qPCR or a P. aeruginosa positive culture
result.
Acknowledgements
Pieter Deschaght is indebted to the IWT for PhD research grant IWT-SB/
71184. This study was funded by the Belgian Cystic Fibrosis Association.
Author details
1Laboratory for Bacteriology Research (LBR), Ghent University Hospital, Ghent
University, Ghent, Belgium. 2Cystic Fibrosis Centre Ghent, Ghent University
Hospital, Ghent, Belgium. 3Cystic Fibrosis Centre, Universitair Ziekenhuis
Brussel, Brussels, Belgium. 4Cystic Fibrosis Centre, Cliniques St Luc, University
of Louvain, Brussels, Belgium. 5Cystic Fibrosis Centre ULB, Hôpital
Universitaire des Enfants Reine Fabiola, Erasme University Hospital, Brussels,
Belgium. 6Cystic Fibrosis Centre Liege, CHR La Citadelle and CHC Espérance,
Liege, Belgium. 7Cystic Fibrosis Centre Antwerp, University Hospital Antwerp,
Antwerp, Belgium.
Authors’ contributions
MV, FDB, SVD, PS and PD conceived the study and designed the
experiments. MV, FDB, PD, PS, SVD wrote the manuscript. PD, LVS, GLdSS
performed the experiments. Authors from other universities provided patient
samples and helped with the manuscript discussion. All authors have read
and approved the final manuscript.
Received: 29 April 2010 Accepted: 24 September 2010
Published: 24 September 2010
References
1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M,
Rozmahel R, Cole JL, Kennedy D, Hidaka N: Identification of the cystic
fibrosis gene: chromosome walking and jumping. Science 1989,
245:1059-1065.
2. Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of
pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003,
168:918-951.
3. Döring G, Gulbins E: Cystic fibrosis and innate immunity: how chloride
channel mutations provoke lung disease. Cell Microbiol 2009, 11:208-216.
4. Kerem E, Corey M, Gold R, Levison H: Pulmonary function and clinical
course in patients with cystic fibrosis after pulmonary colonization with
Pseudomonas aeruginosa. J Pediatr 1990, 116:714-719.
5. Frederiksen B, Koch C, Høiby N: Antibiotic treatment of initial colonization
with Pseudomonas aeruginosa postpones chronic infection and prevents
deterioration of pulmonary function in cystic fibrosis. Ped Pulmon 1997,
23:330-335.
6. Koch C, Høiby N: Prevention of chronic Pseudomonas aeruginosa
colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
7. Vasquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC: Early
treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Acta
Paediatr Scand 1993, 82:308-309.
8. Taylor RFH, Hodson ME, Pitt TL: Adult cystic fibrosis: association of acute
pulmonary exacerbations and increasing severity of lung disease with
auxotrophic mutants of Pseudomonas aeruginosa. Thorax 1993,
48:1002-1005.
9. Xu J, Moore J, Murphy PG, Millar BC, Elborn JS: Early detection of
Pseudomonas aeruginosa - comparison of conventional versus molecular
(PCR) detection directly from adult patients with cystic fibrosis (CF).
Annals Clin Microbiol Antimicrob 2004, 3:21-26.
10. Döring G, Conway SP, Heijerman HGM, Hodson ME, Høiby N, Smyth A,
Touw DJ, for the consensus Group: Antibiotic therapy against
Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur
Respir J 2000, 16:749-767.
11. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation
of a new definition for chronic Pseudomonas aeruginosa infection in
cystic fibrosis patients. J Cyst Fibr 2003, 2:29-34.
12. Schelstraete P, Van daele S, De Boeck K, Proesmans M, Lebecque P,
Leclercq-Foucart J, Malfroot A, Vaneechoutte M, De Baets F: Pseudomonas
aeruginosa in the home environment of newly infected cystic fibrosis
patients. Eur Respir J 2008, 31:822-829.
13. Deschaght P, De Baere T, Van Simaey L, Van daele S, De Baets F, De Vos D,
Pirnay JP, Vaneechoutte M: Comparison of the sensitivity of culture, PCR
and quantitative real-time PCR for the detection of Pseudomonas
aeruginosa in sputum of cystic fibrosis patients. BMC Microbiol 2009,
9:244.
14. Khot PD, Ko DL, Hackman RK, Fredricks DN: Development and
optimization of quantitative PCR for the diagnosis of invasive
aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis 2008, 8:73.
15. Döring G, Unertl K, Heininger A: Validation criteria for nucleic acid
amplification techniques for bacterial infections. Clin Chem Lab Med 2008,
46:909-918.
16. Milagres LG, Castro TLA, Garcia D, Cruz AC, Higa L, Folescu T, Marques EA:
Antibody response to Pseudomonas aeruginosa in children with cystic
fibrosis. Ped Pulmon 2009, 44:392-401.
17. Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Høiby N: Early rise of
anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas
aeruginosa are risk factors for development of chronic lung infection - A
case control study. J Cyst Fibr 2006, 5:9-15.
18. West SEH, Zeng L, Lee BL, Kosorok M, Laxova A, Rock MJ, Splaingard MJ,
Farrell PM: Respiratory infection with Pseudomonas aeruginosa in
children with cystic fibrosis: early detection by serology and assessment
of risk factors. J Am Med Assoc 2000, 287:2958-2967.
19. da Silva Filho LVF, Tateno AF, Martins KM, Chernishev ACA, De Oliveira
Garcia D, Haug M, Meisner C, Rodrigues JC, Döring G: The combination of
PCR and serology increases the diagnosis of Pseudomonas aeruginosa
colonization/infection in cystic fibrosis. Ped Pulmon 2007, 42:938-944.
20. da Silva Filho LVF, Levi JF, Bento CNO, Da Silva Ramos SRT, Rozov T: PCR
identification of Pseudomonas aeruginosa and direct detection in clinical
samples from cystic fibrosis patients. J Med Microbiol 1999, 48:357-361.
21. De Vos D, Lim A, Pirnay JP, Struelens M, Vandenvelde C, Duinslaeger L,
Vanderkelen A, Cornelis P: Direct detection and identification of
Pseudomonas aeruginosa in clinical samples such as skin biopsy
specimens and expectorations by multiplex PCR based on two outer
membrane lipoprotein genes, oprI and oprL. J Clin Microbiol 1997,
35:1295-1299.
Deschaght et al. BMC Microbiology 2010, 10:245
http://www.biomedcentral.com/1471-2180/10/245
Page 5 of 6
22. Karpati F, Jonasson J: Polymerase chain reaction for the detection of
Pseudomonas aeruginosa, Stenotrophomonas maltophilia and
Burkholderia cepacia in sputum of patients with cystic fibrosis. Mol Cell
Probes 1996, 10:397-403.
23. Lavenir R, Jocktane D, Laurent F, Nazaret S, Cournoyer B: Improved
reliability of Pseudomonas aeruginosa PCR detection by the use of the
species-specific ecfX gene target. J Microbiol Meth 2007, 70:20-29.
24. Motoshima M, Yanagihara K, Fukushima K, Matsuda J, Sugahara K,
Hirakata Y, Yamada Y, Kohno S, Kamihira S: Rapid and accurate detection
of Pseudomonas aeruginosa by real-time polymerase chain reaction with
melting curve analysis targeting gyrB gene. Diagn Microbiol Infect Dis
2007, 58:53-58.
25. Motoshima M, Yanagihara K, Yamamoto K, Morinaga Y, Matsuda J,
Sugahara K, Hirakata Y, Yamada Y, Kohno S, Kamihira S: Quantitative
detection of metallo-beta-lactamase of blaIMP-cluster-producing
Pseudomonas aeruginosa by real-time polymerase chain reaction with
melting curve analysis for rapid diagnosis and treatment of nosocomial
infection. Diagn Microbiol Infect Dis 2008, 61:222-226.
26. O’Callaghan EM, Tanner MS, Boulnois GL: Development of a PCR probe
test for identifying Pseudomonas aeruginosa and Pseudomonas
(Burkholderia) cepacia. J Clin Pathol 1994, 47:222-226.
27. Pirnay JP, De Vos D, Duinslaeger L, Reper P, Vandenvelde C, Cornelis P,
Vanderkelen A: Quantitation of Pseudomonas aeruginosa in wound
biopsy samples: from bacterial culture to rapid ‘real-time’ polymerase
chain reaction. Crit Care 2000, 4:255-261.
28. Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL: Use of real-time PCR
with multiple targets to identify Pseudomonas aeruginosa and other
nonfermenting gram-negative bacilli from patients with cystic fibrosis.
J Clin Microbiol 2003, 41:4312-4317.
29. Spilker T, Coenye T, Vandamme P, LiPuma JL: PCR-based assay for
differentiation of Pseudomonas aeruginosa from other Pseudomonas
species recovered from cystic fibrosis patients. J Clin Microbiol 2004,
42:2074-2079.
30. van Belkum A, Renders NHM, Smith S, Overbeek SE, Verbrugh HA:
Comparison of conventional and molecular methods for the detection
of bacterial pathogens in sputum samples from cystic fibrosis. FEMS
Immunol Med Microbiol 2000, 27:51-57.
doi:10.1186/1471-2180-10-245
Cite this article as: Deschaght et al.: Comparison of culture and qPCR
for the detection of Pseudomonas aeruginosa in not chronically infected
cystic fibrosis patients. BMC Microbiology 2010 10:245.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Deschaght et al. BMC Microbiology 2010, 10:245
http://www.biomedcentral.com/1471-2180/10/245
Page 6 of 6
